| Homing peptides |
linear RGD |
PEG |
Ad-ΔE1/Luc |
CAR (-/+) cells |
No |
(114) |
| Ad-ΔE1/Luc |
CAR (-/+) cells |
No |
(115) |
| cyclic RGD |
Ad-ΔE1/IκB |
Down regulation of E-selectin, ICAM-1, VCAM-1, IL-6, IL-18, VEGF A and Tie-2 |
No |
(117) |
| Ad-ΔE1/GFP-Luc |
CAR (-/+) cells |
No |
(116) |
| Ad-ΔE1/GFP-Luc |
In vitro & in vivo bioluminescence imaging |
No, but tumor imaging |
(118) |
| PEG-CBA-DAH |
Oncolytic Ad (Ad-ΔB7-U6shIL8) |
CAR (-/+) cells and oncolytic effects |
No |
(90) |
| SIKVAV |
pHPMA |
Ad-ΔE1/Luc |
α6β1 integrins-positive Prostate cancer cells |
No |
(119) |
| SIGYPLP |
Ad-ΔE1/Luc |
HUVECs |
No |
(120) |
| CGKRK |
PEG |
Ad-ΔE1/HSV-tk |
antitumor effects against primary tumors and metastases |
Yes |
(121) |
| Growth factors |
EGF |
PEG-PCI |
Ad-ΔE1/β-gal |
EGFR (-/+) & CAR (-/+) cells |
No |
(126) |
| pHPMA |
Ad-ΔE1/Luc or Ad-wt |
EGFR (-/+), A549, A9, A9-EGFR And SKOV-luc tumor (i.p.) |
Yes, and tumor imaging |
(127) |
| PEG-biotin |
Avidin-modified Ad-ΔE1/GFP |
EGFR (-/+), A431 (+) and MCF7 (-) |
No |
(128) |
| bFGF or VEGF |
pHPMA |
Ad-ΔE1/β-gal, Ad-ΔE1/GFP |
A9, A9-21, HUVE, A549 |
No |
(52) |
| FGF2 |
PEG |
Ad-ΔE1/Luc or Ad-wt |
FGF (-/+), SKOV3 tumors (i.p.) |
Yes |
(133) |
| Ad-ΔE1/β-gal |
In vivo transduction (SKVO3, i.p.) |
No |
(132) |
| Antibodies |
EGFR |
Cetuximab |
pHPMA |
Ad-ΔE1/Luc or Ad-wt |
EGFR (+) cells but no EGFR phosphorylation |
Yes |
(146) |
| Herceptin |
PEG |
Ad-ΔE1/GFP |
Herceptin (-/+) cells |
No |
(141) |
| Ad-ΔE1/GFP, oncolytic Ad (DWP418) |
Herceptin (-/+) cells, and tumor models of EGFR (+) SKOV3, MDA-MB435 / EGFR (-) MCF7-mot |
Yes |
(142) |
| E-selectin |
pHPMA |
Ad-ΔE1/Luc |
TNF-α-activated HUVECs |
No |
(150) |
| PEG |
Ad-ΔE1/GFP-Luc |
TNF-α-activated HUVECs |
No |
(116) |
| PSMA |
pHPMA |
AΔ-ΔE1/Luc |
PSMA-positive LNCaP |
No |
(151) |
| Natural source |
Folate |
PEG |
Ad-ΔE1/GFP |
Many cancerous cells |
No |
(163) |
